Zevra Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Zevra Therapeutics, Inc. (ZVRA) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $2.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-02-28.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2020-02-28
- Zevra Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-12-31 was -$7.42M.
- Zevra Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-09-30 was $7.42M, a 6.02% increase year-over-year.
- Zevra Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-06-30 was $11.89M, a 43.04% increase year-over-year.
- Zevra Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-03-31 was $17.45M, a 47.46% increase year-over-year.
- Zevra Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2018 was $2.00K, a 99.94% decline from fiscal 2017.
- Zevra Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2017 was $3.09M.
- Zevra Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2016 was -$32.47M, a 219.02% decline from fiscal 2015.
- Zevra Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2015 was $27.28M, a 277.63% increase from fiscal 2014.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|---|---|---|
| 2018-12-31 | -$7.42M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $2.00K derived: sum of 2 quarters · filed 2020-02-28 | $11.89M derived: sum of 3 quarters · filed 2020-02-28 | $2.00K 10-K · filed 2020-02-28 | |||
| 2018-09-30 | $7.42M 10-Q · filed 2018-11-09 | $19.31M derived: sum of 2 quarters · filed 2018-11-09 | $7.42M 10-Q · filed 2018-11-09 | $32.85M derived: sum of 4 quarters · filed 2018-11-09 | |||
| 2018-06-30 | $11.89M 10-Q · filed 2018-08-10 | $11.89M 10-Q · filed 2018-08-10 | $25.43M derived: sum of 3 quarters · filed 2018-08-10 | $32.43M derived: sum of 4 quarters · filed 2018-11-09 | |||
| 2018-03-31 | $17.45M 10-Q · filed 2018-05-11 | $13.54M derived: sum of 2 quarters · filed 2018-05-11 | $20.54M derived: sum of 3 quarters · filed 2018-11-09 | $28.85M derived: sum of 4 quarters · filed 2018-11-09 | |||
| 2017-12-31 | -$3.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | $3.09M derived: sum of 2 quarters · filed 2018-11-09 | $11.40M derived: sum of 3 quarters · filed 2018-11-09 | $3.09M 10-K · filed 2018-03-30 | |||
| 2017-09-30 | $7.00M 10-Q · filed 2018-11-09 | -$1.31M 10-Q · filed 2017-11-09 | $15.31M derived: sum of 2 quarters · filed 2018-11-09 | $7.00M 10-Q · filed 2018-11-09 | $2.38M 10-Q · filed 2017-11-09 | $24.42M derived: sum of 4 quarters · filed 2018-11-09 | |
| 2017-06-30 | $8.31M 10-Q · filed 2018-08-10 | -$3.52M 10-Q · filed 2017-08-10 | $8.31M 10-Q · filed 2018-08-10 | $3.69M 10-Q · filed 2017-08-10 | $17.42M derived: sum of 3 quarters · filed 2018-08-10 | $18.72M derived: sum of 4 quarters · filed 2018-08-10 | |
| 2017-03-31 | $11.83M 10-Q · filed 2018-05-11 | $7.22M 10-Q · filed 2017-05-22 | $9.11M derived: sum of 2 quarters · filed 2018-05-11 | $10.41M derived: sum of 3 quarters · filed 2018-05-11 | -$10.35M derived: sum of 4 quarters · filed 2018-05-11 | ||
| 2016-12-31 | -$2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | -$1.42M derived: sum of 2 quarters · filed 2018-03-30 | -$22.19M derived: sum of 3 quarters · filed 2018-03-30 | -$32.47M 10-K · filed 2018-03-30 | |||
| 2016-09-30 | $1.30M 10-Q · filed 2017-11-09 | -$19.46M derived: sum of 2 quarters · filed 2017-11-09 | -$29.74M 10-Q · filed 2017-11-09 | -$28.98M derived: sum of 4 quarters · filed 2017-11-09 | |||
| 2016-06-30 | -$20.76M 10-Q · filed 2017-08-10 | -$31.04M 10-Q · filed 2017-08-10 | -$30.28M derived: sum of 3 quarters · filed 2017-08-10 | -$28.19M derived: sum of 4 quarters · filed 2017-08-10 | |||
| 2016-03-31 | -$10.28M 10-Q · filed 2017-05-22 | -$9.51M derived: sum of 2 quarters · filed 2017-05-22 | -$7.42M derived: sum of 3 quarters · filed 2017-05-22 | $15.24M derived: sum of 4 quarters · filed 2017-05-22 | |||
| 2015-12-31 | $764.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $2.85M derived: sum of 2 quarters · filed 2017-03-10 | $25.51M derived: sum of 3 quarters · filed 2017-03-10 | $27.28M 10-K · filed 2017-03-10 | |||
| 2015-09-30 | $2.09M 10-Q · filed 2016-11-10 | $24.75M derived: sum of 2 quarters · filed 2016-11-10 | $26.51M 10-Q · filed 2016-11-10 | $29.73M derived: sum of 4 quarters · filed 2016-11-10 | |||
| 2015-06-30 | $22.66M 10-Q · filed 2016-08-11 | $24.42M 10-Q · filed 2016-08-11 | $27.64M derived: sum of 3 quarters · filed 2016-08-11 | $29.83M derived: sum of 4 quarters · filed 2016-08-11 | |||
| 2015-03-31 | $1.76M 10-Q · filed 2016-05-13 | $4.98M derived: sum of 2 quarters · filed 2016-05-13 | $7.17M derived: sum of 3 quarters · filed 2016-05-13 | ||||
| 2014-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-16 | $5.41M derived: sum of 2 quarters · filed 2016-03-16 | $7.22M 10-K · filed 2016-03-16 | ||||
| 2014-09-30 | $2.19M 10-Q · filed 2015-11-13 | $4.00M 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |